BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 30485487)

  • 1. Thyrotrophin receptor antibody concentration and activity, several years after treatment for Graves' disease.
    Nalla P; Young S; Sanders J; Carter J; Adlan MA; Kabelis K; Chen S; Furmaniak J; Rees Smith B; Premawardhana LDKE
    Clin Endocrinol (Oxf); 2019 Feb; 90(2):369-374. PubMed ID: 30485487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The relationship between serum thyroid autoantibodies, iodine intake, development and prognosis of Graves' disease].
    Chen W; Man N; Li YS; Shan ZY; Teng WP
    Zhonghua Nei Ke Za Zhi; 2006 Feb; 45(2):95-9. PubMed ID: 16624113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies.
    Eckstein AK; Plicht M; Lax H; Hirche H; Quadbeck B; Mann K; Steuhl KP; Esser J; Morgenthaler NG
    Clin Endocrinol (Oxf); 2004 Nov; 61(5):612-8. PubMed ID: 15521965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment.
    Quadbeck B; Hoermann R; Hahn S; Roggenbuck U; Mann K; Janssen OE
    Horm Metab Res; 2005 Dec; 37(12):745-50. PubMed ID: 16372228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves' patients and in 686 normal subjects.
    Takasu N; Oshiro C; Akamine H; Komiya I; Nagata A; Sato Y; Yoshimura H; Ito K
    J Endocrinol Invest; 1997 Sep; 20(8):452-61. PubMed ID: 9364248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in the properties of the thyrotropin receptor antibody in patients with Graves' disease after radioiodine treatment.
    Cho BY; Shong YK; Chung JK; Lee MC; Lee HK; Koh CS; Min HK
    Thyroidology; 1989 Dec; 1(3):109-14. PubMed ID: 2484872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of TSH receptor antibody by 'natural in vivo human assay' in neonates born to mothers with Graves' disease.
    Tamaki H; Amino N; Iwatani Y; Tachi J; Kimura M; Mitsuda N; Ichihara K; Tanizawa O; Miyai K
    Clin Endocrinol (Oxf); 1989 May; 30(5):493-503. PubMed ID: 2575017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stimulating and blocking thyroid-stimulating hormone (TSH) receptor autoantibodies from patients with Graves' disease and autoimmune hypothyroidism have very similar concentration, TSH receptor affinity, and binding sites.
    Morgenthaler NG; Ho SC; Minich WB
    J Clin Endocrinol Metab; 2007 Mar; 92(3):1058-65. PubMed ID: 17179194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in the properties of the thyrotropin receptor antibody in patients with Graves' disease after radioiodine treatment.
    Cho BY; Shong YK; Chung JK; Lee MC; Lee HK; Koh CS; Min HK
    Korean J Intern Med; 1990 Jan; 5(1):51-7. PubMed ID: 1980206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of radioiodine treatment on the characteristics of TRAb in Graves' disease.
    Fang Y; Du WH; Zhang CX; Zhao SX; Song HD; Gao GQ; Dong M
    BMC Endocr Disord; 2021 Nov; 21(1):238. PubMed ID: 34847904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TSH-receptor antibodies determined by the first, second and third generation assays and thyroid-stimulating antibody in pregnant patients with Graves' disease.
    Kamijo K
    Endocr J; 2007 Aug; 54(4):619-24. PubMed ID: 17641440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay.
    Maugendre D; Massart C
    Clin Endocrinol (Oxf); 2001 Jan; 54(1):89-96. PubMed ID: 11167931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study.
    Laurberg P; Wallin G; Tallstedt L; Abraham-Nordling M; Lundell G; Tørring O
    Eur J Endocrinol; 2008 Jan; 158(1):69-75. PubMed ID: 18166819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of new different assay systems for thyrotropin receptor antibodies with reference to thyroid-stimulating antibodies and thyroid stimulation-blocking antibodies in Graves' disease.
    Hirooka Y; Li C; Takagi J; Gotoh M; Habu S; Yasaka-Nomura T; Ishihara R; Nakasone Y; Nakamura R; Morikawa R; Otake K; Nogimori T; Ishizuki Y
    Int J Clin Pharmacol Res; 2004; 24(4):111-6. PubMed ID: 15754915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TSBAb (TSH-stimulation blocking antibody) and TSAb (thyroid stimulating antibody) in TSBAb-positive patients with hypothyroidism and Graves' patients with hyperthyroidism.
    Takasu N; Yamashiro K; Ochi Y; Sato Y; Nagata A; Komiya I; Yoshimura H
    Horm Metab Res; 2001 Apr; 33(4):232-7. PubMed ID: 11383928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effects of radioiodine on thyrotrophin receptor antibodies in Graves' disease.
    Aizawa Y; Yoshida K; Kaise N; Kaise K; Fukazawa H; Kiso Y; Mori K; Sayama N; Kikuchi K; Abe K
    Clin Endocrinol (Oxf); 1995 May; 42(5):517-22. PubMed ID: 7621571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thyrotrophin receptor antibody characteristics in a woman with long-standing Hashimoto's who developed Graves' disease and pretibial myxoedema.
    Kamath C; Young S; Kabelis K; Sanders J; Adlan MA; Furmaniak J; Rees Smith B; Premawardhana LD
    Clin Endocrinol (Oxf); 2012 Sep; 77(3):465-70. PubMed ID: 22891608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential evolution of thyroid peroxidase and thyrotropin receptor antibodies in Graves' disease: thyroid peroxidase antibody activity reverts to pretreatment level after carbimazole withdrawal.
    Guilhem I; Massart C; Poirier JY; Maugendre D
    Thyroid; 2006 Oct; 16(10):1041-5. PubMed ID: 17042691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thyrotropin Receptor Antibody Levels at Diagnosis and After Thionamide Course Predict Graves' Disease Relapse.
    Tun NN; Beckett G; Zammitt NN; Strachan MW; Seckl JR; Gibb FW
    Thyroid; 2016 Aug; 26(8):1004-9. PubMed ID: 27266892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum thyrotropin-receptor autoantibodies levels after I therapy in Graves' patients: effect of pretreatment with methimazole evaluated by a prospective, randomized study.
    Andrade VA; Gross JL; Maia AL
    Eur J Endocrinol; 2004 Oct; 151(4):467-74. PubMed ID: 15476447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.